Sponsored by
This is an interesting new paper from researchers at Yale, Massachusetts General Hospital, the Weizmann Institute of Science, and the University of Miami.
Using one of the largest longitudinal single-cell datasets in IDH-mutant glioma, the researchers showed that progression can occur through both genetic evolution and cell-state changes. In some tumors, acquired genetic alterations expand proliferative, stem-like cell populations. In others, tumors adopt a mesenchymal-like state associated with immune suppression and poorer outcomes, even without major new genetic changes.
Thus, treatment resistance is not necessarily driven solely by accumulating mutations. Instead, tumors under treatment pressure can evolve toward distinct biological trajectories, including stem-like or more glioblastoma-like programs. Two IDH-mutant gliomas could have similar DNA yet behave very differently because of the cell types and cellular programs active within the tumor. Single-cell sequencing is a powerful tool for capturing these differences, and as our understanding of these evolutionary trajectories improves, it may help identify early warning signs of resistance, predict treatment response, and potentially guide strategies to keep tumors on more treatment-sensitive paths.